Reyon Pharmaceutical Co Ltd (102460) - Total Liabilities

Latest as of September 2025: ₩239.99 Billion KRW ≈ $162.63 Million USD

Based on the latest financial reports, Reyon Pharmaceutical Co Ltd (102460) has total liabilities worth ₩239.99 Billion KRW (≈ $162.63 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore 102460 long-term asset investment ratio to see how much of total assets are deployed in long-term investments.

Reyon Pharmaceutical Co Ltd - Total Liabilities Trend (2008–2024)

This chart illustrates how Reyon Pharmaceutical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Reyon Pharmaceutical Co Ltd balance sheet assets.

Reyon Pharmaceutical Co Ltd Competitors by Total Liabilities

The table below lists competitors of Reyon Pharmaceutical Co Ltd ranked by their total liabilities.

Company	Country	Total Liabilities
Shimmick Corporation Common Stock NASDAQ:SHIM	USA	$275.40 Million
Teladan Setia Group Bhd KLSE:0230	Malaysia	RM398.22 Million
Spring Valley Acquisition Corp. II Class A Ordinary Shares NASDAQ:SVII	USA	$5.87 Million
Etga Group Ltd TA:ETGA	Israel	ILA809.39 Million
ABL Group ASA OL:ABL	Norway	Nkr114.59 Million
Wam Research Ltd AU:WAX	Australia	AU$17.07 Million
Black Mammoth Metals Corp V:BMM	Canada	CA$927.13K
Quanterix Corp NASDAQ:QTRX	USA	$82.42 Million

Liability Composition Analysis (2008–2024)

This chart breaks down Reyon Pharmaceutical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See 102460 net asset quality index to measure how much of total assets are equity-financed.

Liquidity & Leverage Metrics

Key Metrics Explained

Metric	Value	Description
Current Ratio	0.60	Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities)
Quick Ratio	N/A	More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities)
Cash Ratio	N/A	Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities)
Debt to Equity	1.03	Measures financial leverage (Total Liabilities ÷ Shareholder Equity)
Debt to Assets	0.51	Portion of assets financed with debt (Total Liabilities ÷ Total Assets)

Liability Trends Comparison

This chart compares key liability metrics across different time periods, showing how Reyon Pharmaceutical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.

Annual Total Liabilities for Reyon Pharmaceutical Co Ltd (2008–2024)

The table below shows the annual total liabilities of Reyon Pharmaceutical Co Ltd from 2008 to 2024.

Year	Total Liabilities	Change
2024-12-31	₩250.05 Billion ≈ $169.46 Million	-0.44%
2023-12-31	₩251.15 Billion ≈ $170.20 Million	+6.00%
2022-12-31	₩236.93 Billion ≈ $160.56 Million	+1.80%
2021-12-31	₩232.74 Billion ≈ $157.73 Million	+165.93%
2020-12-31	₩87.52 Billion ≈ $59.31 Million	+67.69%
2019-12-31	₩52.19 Billion ≈ $35.37 Million	-32.90%
2018-12-31	₩77.77 Billion ≈ $52.71 Million	+9.27%
2017-12-31	₩71.18 Billion ≈ $48.24 Million	+133.83%
2016-12-31	₩30.44 Billion ≈ $20.63 Million	-0.42%
2012-12-31	₩30.57 Billion ≈ $20.72 Million	+6.39%
2011-12-31	₩28.73 Billion ≈ $19.47 Million	+29.70%
2009-12-31	₩22.15 Billion ≈ $15.01 Million	-2.14%
2008-12-31	₩22.64 Billion ≈ $15.34 Million	--

About Reyon Pharmaceutical Co Ltd

KO:102460 Korea Drug Manufacturers - Specialty & Generic

Market Cap

$125.41 Million

₩185.06 Billion KRW

Market Cap Rank

#18432 Global

#826 in Korea

Share Price

₩10090.00

Change (1 day)

+0.20%

52-Week Range

₩9770.00 - ₩12570.00

All Time High

₩70413.22